卡维地洛和匹伐他汀对泰乐菌素诱导的 Wistar 大鼠高脂血症的抗高脂血症活性的比较评价

Md. Akbar , Hasan Ali , Md. Azizur Rahman
{"title":"卡维地洛和匹伐他汀对泰乐菌素诱导的 Wistar 大鼠高脂血症的抗高脂血症活性的比较评价","authors":"Md. Akbar ,&nbsp;Hasan Ali ,&nbsp;Md. Azizur Rahman","doi":"10.1016/j.ipha.2023.11.009","DOIUrl":null,"url":null,"abstract":"<div><p>Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 ​mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 ​mg/kg) on 8th day. The treated group-III received 10 ​mg/kg carvedilol and group-IV received 20 ​mg/kg carvedilol for eight days and tyloxapol (400 ​mg/kg) on the 8th day. The group-V received pitavastatin (0.3 ​mg/kg) for eight days and tyloxapol (400 ​mg/kg) on the 8th day. The group-VI received carvedilol (20 ​mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 2","pages":"Pages 226-231"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001235/pdfft?md5=8b316c7007423929357be787f7e0c207&pid=1-s2.0-S2949866X23001235-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats\",\"authors\":\"Md. Akbar ,&nbsp;Hasan Ali ,&nbsp;Md. Azizur Rahman\",\"doi\":\"10.1016/j.ipha.2023.11.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 ​mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 ​mg/kg) on 8th day. The treated group-III received 10 ​mg/kg carvedilol and group-IV received 20 ​mg/kg carvedilol for eight days and tyloxapol (400 ​mg/kg) on the 8th day. The group-V received pitavastatin (0.3 ​mg/kg) for eight days and tyloxapol (400 ​mg/kg) on the 8th day. The group-VI received carvedilol (20 ​mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.</p></div>\",\"PeriodicalId\":100682,\"journal\":{\"name\":\"Intelligent Pharmacy\",\"volume\":\"2 2\",\"pages\":\"Pages 226-231\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23001235/pdfft?md5=8b316c7007423929357be787f7e0c207&pid=1-s2.0-S2949866X23001235-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Intelligent Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23001235\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949866X23001235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在探讨卡维地洛和匹伐他汀对泰乐沙醇诱导的 Wistar 大鼠高脂血症的抗高脂血症活性。大鼠随机分为 6 组。载体对照组-I 接受 2 mL 生理盐水,为期 8 天。病理对照组-II在第8天接受泰乐沙醇(400毫克/千克)治疗。治疗组-III接受10毫克/千克卡维地洛治疗,组-IV接受20毫克/千克卡维地洛治疗8天,并在第8天接受tyloxapol(400毫克/千克)治疗。第五组连续八天服用匹伐他汀(0.3 毫克/千克),第八天服用泰乐沙波尔(400 毫克/千克)。第六组只接受卡维地洛(20 毫克/千克)治疗八天。治疗八天后,使用凝胶电泳法对血清和心肌组织中的甘油三酯、总胆固醇、高密度脂蛋白、极低密度脂蛋白、硫代巴比妥酸活性物质和谷胱甘肽以及肝组织的 DNA 片段进行了估测。给tyloxapol诱导的高脂血症大鼠口服卡维地洛,可使上述参数的变化趋于正常,且呈剂量依赖性。因此,卡维地洛联合匹伐他汀对泰乐沙醇诱导的 Wistar 大鼠高脂血症具有抗高脂血症活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats

Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 ​mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 ​mg/kg) on 8th day. The treated group-III received 10 ​mg/kg carvedilol and group-IV received 20 ​mg/kg carvedilol for eight days and tyloxapol (400 ​mg/kg) on the 8th day. The group-V received pitavastatin (0.3 ​mg/kg) for eight days and tyloxapol (400 ​mg/kg) on the 8th day. The group-VI received carvedilol (20 ​mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial Board Editorial Board Cardioprotective potential of Rosuvastatin against isoproterenol induced cardiac dysfunction and hypertrophy in the experimental model of rodents Sea buckthorn: A potential dietary supplement with multifaceted therapeutic activities Design of some potent non-toxic Autoimmune disorder inhibitors based on 2D-QSAR, CoMFA, molecular docking, and molecular dynamics investigations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1